NV
Novartis
NVS · NYSE
$160.00 -1.89% (-$3.09)
1M +2.34%
Market Cap $309.9B
P/E Ratio 24.29x
Div. Yield 2.91%
ROE 29.93%
Bulios Fair Price
$213.68
33.6% upside
Trenutna cena
$160
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NVS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
6/9Valuation
48 /100
Fair P/B 7.46x
P/S 5.57x
P/E 24.29x
Growth
69 /100
Growing Book val. growth 8.05%
FCF growth 13.81%
EPS growth 31.39%
Profitability
100 /100
Strong FCF margin 28.43%
Op. margin 30.54%
Gross margin 74.44%
Quality
79 /100
Excellent Asset turnover 0.46x
ROA 10.46%
ROIC 13.93%
Debt
61 /100
Moderate Net debt/EBITDA 1.86x
Int. coverage 12.17x
Debt/Equity 1.18x
Stability
64 /100
Moderate Profitable years 6
EPS volatility 72.86%
Beta 0.46x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NVS
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Vasant Narasimhan
Employees
75,267
Headquarters
Basel
Prihajajoči dogodki
27 OKT.
Earnings
Upcoming earnings report